Juan Harrison is a biotechnology and pharmaceutical executive focused on company formation, strategy, partnering, venture investment and licensing transactions. In his current role at IMIDomics, he is leading the company as it works to discover and develop new medicines for the treatment of patients with immune-mediated inflammatory diseases. He was previously Vice President and head of Strategic Academic Alliances (SAA) at Takeda Pharmaceuticals where he was responsible for establishing several broad drug discovery alliances. Before leading Takeda’s SAA, he was vice president at Takeda Ventures where he invested in several companies including Envoy Therapeutics, later acquired by Takeda. Harrison has also held senior positions in Alza Pharmaceuticals, Connetics, PowderJect and XenoPort.
AI & Data Science Showcase:
With strong roots in Spain and an established presence in the United States, IMIDomics is a global biotechnology company focused on the discovery and development of new medicines for the treatment of patients with immune-mediated inflammatory diseases (IMIDs).
IMIDomics’ Precision Discovery Platform Enables Precision Medicine
IMIDomics believes that a deep understanding of patients, their clinical condition and underlying biology will lead to next generation medicines. Juan Harrison will showcase how IMIDomics discovers and develops precision medicines for IMIDs using its proprietary data-powered system.
The PMWC 2022 AI Company Showcase will provide a 15-minute time slot for selected AI companies to present their latest technologies to an audience of leading investors, potential clients, and partners. We will hear from companies building technologies that expedite the pre-clinical and clinical drug discovery and development process, accelerate patient diagnosis and treatment, or develop scalable systems framework to make AI and deep/machine learning a reality.